Wyeth Pharmaceuticals reported promising results for bazedoxifene from a placebo-controlled Phase 3 study. The drug, a selective estrogen receptor modulator (SERM), is under clinical investigation for the prevention and treatment of postmenopausal osteoporosis. The trial of bazedoxifene 20 mg indicated a significant reduction in new vertebral fractures in postmenopausal women with osteoporosis.